Taxanes and gemcitabine doublets in the management of HER-2 negative metastatic breast cancer: Towards optimization of association and schedule

Giulio Metro, Alessandra Fabi, Michelangelo Russillo, Paola Papaldo, Michelino De Laurentiis, Gianluigi Ferretti, Domenica Pellegrini, Carmen Nuzzo, Vanessa Graziano, Patrizia Vici, Marianna Introna, Alessandra Felici, Francesco Cognetti, Paolo Carlini

Research output: Contribution to journalArticle

Abstract

The management of human epidermal receptor-2 (HER-2) negative metastatic breast cancer (MBC) is usually problematic, since no standard therapy exists in this setting. For some patients, combination chemotherapy represents a valuable approach, although its use is often limited by the risks of increased toxicity as well as impairments in quality of life (QoL) that often outweigh the marginal efficacy benefit. Against this background, the use of taxanes, either paclitaxel or docetaxel, in combination with gemcitabine as first-line treatment of HER-2 negative MBC is supported by the evidence of the single-agent activity of these drugs, beneficial pharmacological interactions, different mechanisms of action and largely non superimposable toxicity profiles. A number of phase II studies have explored the activity of a taxane plus gemcitabine in both chemonaïve and pretreated MBC patients, all showing remarkably high response rates and exceptional tolerability. In randomized phase III trials, the paclitaxel and gemcitabine combination showed significant improvements in objective responses, time to progression and overall survival, as compared to paclitaxel monotherapy, whereas the docetaxel and gemcitabine doublet demonstrated equal efficacy and better tolerability, as compared to docetaxel plus capecitabine. In addition to standard threeweekly dosing regimens, alternative schedules of administration of taxanes and gemcitabine doublets (weekly, twoweekly) might deserve further investigation due to their potential usefulness in reducing pharmacological toxicity while maintaining or increasing dose-intensity and clinical efficacy. Furthermore, uncertainty exists on which taxane should be preferred in combination with gemcitabine, since no head-to-head comparison between paclitaxel-gemcitabine and docetaxel-gemcitabine has been performed so far. Ongoing trials will address these issues and future investigations will also include the evaluation of bevacizumab, the monoclonal antibody targeted against vascular endothelial growth factor (VEGF), in combination with taxanes and gemcitabine doublets.

Original languageEnglish
Pages (from-to)1245-1258
Number of pages14
JournalAnticancer Research
Volume28
Issue number2 B
Publication statusPublished - Mar 2008

Fingerprint

gemcitabine
Taxoids
docetaxel
Appointments and Schedules
Breast Neoplasms
Paclitaxel
Pharmacology
Combination Drug Therapy

Keywords

  • Docetaxel
  • First-line chemotherapy
  • Gemcitabine
  • HER-2
  • Metastatic breast cancer
  • Paclitaxel
  • Review
  • Taxane

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Taxanes and gemcitabine doublets in the management of HER-2 negative metastatic breast cancer : Towards optimization of association and schedule. / Metro, Giulio; Fabi, Alessandra; Russillo, Michelangelo; Papaldo, Paola; De Laurentiis, Michelino; Ferretti, Gianluigi; Pellegrini, Domenica; Nuzzo, Carmen; Graziano, Vanessa; Vici, Patrizia; Introna, Marianna; Felici, Alessandra; Cognetti, Francesco; Carlini, Paolo.

In: Anticancer Research, Vol. 28, No. 2 B, 03.2008, p. 1245-1258.

Research output: Contribution to journalArticle

Metro, G, Fabi, A, Russillo, M, Papaldo, P, De Laurentiis, M, Ferretti, G, Pellegrini, D, Nuzzo, C, Graziano, V, Vici, P, Introna, M, Felici, A, Cognetti, F & Carlini, P 2008, 'Taxanes and gemcitabine doublets in the management of HER-2 negative metastatic breast cancer: Towards optimization of association and schedule', Anticancer Research, vol. 28, no. 2 B, pp. 1245-1258.
Metro, Giulio ; Fabi, Alessandra ; Russillo, Michelangelo ; Papaldo, Paola ; De Laurentiis, Michelino ; Ferretti, Gianluigi ; Pellegrini, Domenica ; Nuzzo, Carmen ; Graziano, Vanessa ; Vici, Patrizia ; Introna, Marianna ; Felici, Alessandra ; Cognetti, Francesco ; Carlini, Paolo. / Taxanes and gemcitabine doublets in the management of HER-2 negative metastatic breast cancer : Towards optimization of association and schedule. In: Anticancer Research. 2008 ; Vol. 28, No. 2 B. pp. 1245-1258.
@article{0c924ee9235c41858b88a5dfa06294f5,
title = "Taxanes and gemcitabine doublets in the management of HER-2 negative metastatic breast cancer: Towards optimization of association and schedule",
abstract = "The management of human epidermal receptor-2 (HER-2) negative metastatic breast cancer (MBC) is usually problematic, since no standard therapy exists in this setting. For some patients, combination chemotherapy represents a valuable approach, although its use is often limited by the risks of increased toxicity as well as impairments in quality of life (QoL) that often outweigh the marginal efficacy benefit. Against this background, the use of taxanes, either paclitaxel or docetaxel, in combination with gemcitabine as first-line treatment of HER-2 negative MBC is supported by the evidence of the single-agent activity of these drugs, beneficial pharmacological interactions, different mechanisms of action and largely non superimposable toxicity profiles. A number of phase II studies have explored the activity of a taxane plus gemcitabine in both chemona{\"i}ve and pretreated MBC patients, all showing remarkably high response rates and exceptional tolerability. In randomized phase III trials, the paclitaxel and gemcitabine combination showed significant improvements in objective responses, time to progression and overall survival, as compared to paclitaxel monotherapy, whereas the docetaxel and gemcitabine doublet demonstrated equal efficacy and better tolerability, as compared to docetaxel plus capecitabine. In addition to standard threeweekly dosing regimens, alternative schedules of administration of taxanes and gemcitabine doublets (weekly, twoweekly) might deserve further investigation due to their potential usefulness in reducing pharmacological toxicity while maintaining or increasing dose-intensity and clinical efficacy. Furthermore, uncertainty exists on which taxane should be preferred in combination with gemcitabine, since no head-to-head comparison between paclitaxel-gemcitabine and docetaxel-gemcitabine has been performed so far. Ongoing trials will address these issues and future investigations will also include the evaluation of bevacizumab, the monoclonal antibody targeted against vascular endothelial growth factor (VEGF), in combination with taxanes and gemcitabine doublets.",
keywords = "Docetaxel, First-line chemotherapy, Gemcitabine, HER-2, Metastatic breast cancer, Paclitaxel, Review, Taxane",
author = "Giulio Metro and Alessandra Fabi and Michelangelo Russillo and Paola Papaldo and {De Laurentiis}, Michelino and Gianluigi Ferretti and Domenica Pellegrini and Carmen Nuzzo and Vanessa Graziano and Patrizia Vici and Marianna Introna and Alessandra Felici and Francesco Cognetti and Paolo Carlini",
year = "2008",
month = "3",
language = "English",
volume = "28",
pages = "1245--1258",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "2 B",

}

TY - JOUR

T1 - Taxanes and gemcitabine doublets in the management of HER-2 negative metastatic breast cancer

T2 - Towards optimization of association and schedule

AU - Metro, Giulio

AU - Fabi, Alessandra

AU - Russillo, Michelangelo

AU - Papaldo, Paola

AU - De Laurentiis, Michelino

AU - Ferretti, Gianluigi

AU - Pellegrini, Domenica

AU - Nuzzo, Carmen

AU - Graziano, Vanessa

AU - Vici, Patrizia

AU - Introna, Marianna

AU - Felici, Alessandra

AU - Cognetti, Francesco

AU - Carlini, Paolo

PY - 2008/3

Y1 - 2008/3

N2 - The management of human epidermal receptor-2 (HER-2) negative metastatic breast cancer (MBC) is usually problematic, since no standard therapy exists in this setting. For some patients, combination chemotherapy represents a valuable approach, although its use is often limited by the risks of increased toxicity as well as impairments in quality of life (QoL) that often outweigh the marginal efficacy benefit. Against this background, the use of taxanes, either paclitaxel or docetaxel, in combination with gemcitabine as first-line treatment of HER-2 negative MBC is supported by the evidence of the single-agent activity of these drugs, beneficial pharmacological interactions, different mechanisms of action and largely non superimposable toxicity profiles. A number of phase II studies have explored the activity of a taxane plus gemcitabine in both chemonaïve and pretreated MBC patients, all showing remarkably high response rates and exceptional tolerability. In randomized phase III trials, the paclitaxel and gemcitabine combination showed significant improvements in objective responses, time to progression and overall survival, as compared to paclitaxel monotherapy, whereas the docetaxel and gemcitabine doublet demonstrated equal efficacy and better tolerability, as compared to docetaxel plus capecitabine. In addition to standard threeweekly dosing regimens, alternative schedules of administration of taxanes and gemcitabine doublets (weekly, twoweekly) might deserve further investigation due to their potential usefulness in reducing pharmacological toxicity while maintaining or increasing dose-intensity and clinical efficacy. Furthermore, uncertainty exists on which taxane should be preferred in combination with gemcitabine, since no head-to-head comparison between paclitaxel-gemcitabine and docetaxel-gemcitabine has been performed so far. Ongoing trials will address these issues and future investigations will also include the evaluation of bevacizumab, the monoclonal antibody targeted against vascular endothelial growth factor (VEGF), in combination with taxanes and gemcitabine doublets.

AB - The management of human epidermal receptor-2 (HER-2) negative metastatic breast cancer (MBC) is usually problematic, since no standard therapy exists in this setting. For some patients, combination chemotherapy represents a valuable approach, although its use is often limited by the risks of increased toxicity as well as impairments in quality of life (QoL) that often outweigh the marginal efficacy benefit. Against this background, the use of taxanes, either paclitaxel or docetaxel, in combination with gemcitabine as first-line treatment of HER-2 negative MBC is supported by the evidence of the single-agent activity of these drugs, beneficial pharmacological interactions, different mechanisms of action and largely non superimposable toxicity profiles. A number of phase II studies have explored the activity of a taxane plus gemcitabine in both chemonaïve and pretreated MBC patients, all showing remarkably high response rates and exceptional tolerability. In randomized phase III trials, the paclitaxel and gemcitabine combination showed significant improvements in objective responses, time to progression and overall survival, as compared to paclitaxel monotherapy, whereas the docetaxel and gemcitabine doublet demonstrated equal efficacy and better tolerability, as compared to docetaxel plus capecitabine. In addition to standard threeweekly dosing regimens, alternative schedules of administration of taxanes and gemcitabine doublets (weekly, twoweekly) might deserve further investigation due to their potential usefulness in reducing pharmacological toxicity while maintaining or increasing dose-intensity and clinical efficacy. Furthermore, uncertainty exists on which taxane should be preferred in combination with gemcitabine, since no head-to-head comparison between paclitaxel-gemcitabine and docetaxel-gemcitabine has been performed so far. Ongoing trials will address these issues and future investigations will also include the evaluation of bevacizumab, the monoclonal antibody targeted against vascular endothelial growth factor (VEGF), in combination with taxanes and gemcitabine doublets.

KW - Docetaxel

KW - First-line chemotherapy

KW - Gemcitabine

KW - HER-2

KW - Metastatic breast cancer

KW - Paclitaxel

KW - Review

KW - Taxane

UR - http://www.scopus.com/inward/record.url?scp=42549129903&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=42549129903&partnerID=8YFLogxK

M3 - Article

C2 - 18505062

AN - SCOPUS:42549129903

VL - 28

SP - 1245

EP - 1258

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 2 B

ER -